The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
Browsing: breast cancer
General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
The idea of using harmful bacteria to treat disease might strike many as an odd concept.